TheraCIM (Nimotuzumab)

TheraCIM is not chemotherapy. It is a type of targeted cancer therapy known as a monoclonal antibody. TheraCIM is a recombinant humanized monoclonal antibody designed to target and binds specifically to human Epidermal Growth Factor Receptor (EGFR) and blocks its activity. Excessive production of EGFR is observed in a variety of tumors and associated with poor treatment response, disease progression, and poor prognosis.

The EGF receptor is expressed on numerous non-cancerous cells, including skin cells, GI mucosa, and renal cells, while over-expressed on many types of cancer cells. TheraCIM discriminates between normal cells and cancer cells, binding preferentially to cancer cells over-expressing EGFR.

TheraCIM has been studied in brain tumors, head and neck cancers, nasopharyngeal carcinoma and many other solid tumors in numerous clinical studies. It has demonstrated evidence of no severe skin rash in and other side-effects commonly associated with anti-EGFR treatment, with its efficacy being equivalent or superior to those of other anti-EGFR.

To know more about TheraCIM and how it may help you or your love ones, you may reach us:

TheraCIM support team strives to get back to you at the earliest.